Premium
Further clinical studies with intrahepatic arterial infusion with 5‐fluorouracil
Author(s) -
Ansfield Fred J.,
Ramirez Guillermo,
Davis Hugh L.,
Wirtanen George W.,
Johnson Robert O.,
Bryan George T.,
Manalo Felipe B.,
Borden Ernest C.,
Davis Thomas E.,
Esmaili Muhammad
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197512)36:6<2413::aid-cncr2820360621>3.0.co;2-3
Subject(s) - medicine , fluorouracil , surgery , catheter , survival rate , continuous infusion , hepatic arterial infusion , toxicity , chemotherapy , gastroenterology , metastasis , cancer
A total of 419 patients with progressive liver disease, in nearly all cases metastatic from gastrointestinal primaries, were treated by intrahepatic arterial infusion with 5‐FU. Three‐fourths of these patients had had prior trials with intravenous 5‐FU for 1 or 2 months to several years and had been switched to the infusion upon the development of progression. Catheters were placed percutaneously and the patients infused with 5‐FU at a dose of 20 to 30 mg kg/day × 4, then 15 mg/kg/day × 17, at which point the catheter was removed and the patient sent home on weekly i.v. doses at 15 mg/kg. Toxicity, morbidity, and mortality were minimal with the intrahepatic arterial infusion treatment and the rigid criteria of improvement were met by 55% of the study cases. The survival rate of those patients who responded to the treatment was greater than the survival rate of those who failed to respond.